Our history began in 2011 but our operations have over the years resulted in the foundation, investment and acquisitions of multiple companies. MSC has been focused on strategy and communication assignments throughout this time and has continued to be profitable and grow organically since it was formed in 2014. Now, we have a track record of having worked with roughly 90 different clients in the various fields of Life Science. Our experience ranges across all indication areas but with a higher representation in oncology, inflammation, autoimmunity, CNS and infectious diseases.

Overall, we have delivered about of 80+ asset/portfolio valuations that have been used for asset licensing, company acquisition, investment negotiation and preparation for IPOs. However, we have probably done at least twice as many market opportunity analysis projects covering everything from immuno-oncology, rare diseases, cell & gene therapies, specific receptor target landscapes, point-of-care technologies, RNA platforms, CROs/CDMOs, investors, Big Pharma portfolio strategies and much more.

It is fair to say that we are Life Science generalists specialized in business development, valuation and communication in the Nordics. Our ambition is to maintain a healthy mix of long-term partnerships and shorter client engagements. We thrive when our clients succeed.

Why do our clients keep coming back?

It is simple, because of our team! We are a diverse bunch of ambitious, hard-working and energetic people with a fervor for the Life Science industry. While we come from different backgrounds, we share a passion with our clients to drive the future of medicine.

Do you see yourself working with us?

Check out our vacancies